These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18654067)

  • 1. Concerns about the safety of obesity agents from a manufacturing perspective.
    Kanfer I
    Postgrad Med; 2008 Jul; 120(2):42-5. PubMed ID: 18654067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What makes a generic medication generic?
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2009 Dec; 47(12):17-20. PubMed ID: 20000278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
    Verbeeck RK; Kanfer I; Walker RB
    Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.
    Meredith PA
    Curr Med Res Opin; 2009 Sep; 25(9):2179-89. PubMed ID: 19601710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic substitution: issues for problematic drugs.
    Henderson JD; Esham RH
    South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residues of genotoxic alkyl mesylates in mesylate salt drug substances: real or imaginary problems?
    Snodin DJ
    Regul Toxicol Pharmacol; 2006 Jun; 45(1):79-90. PubMed ID: 16564608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of generic agents in psychopharmacologic treatment.
    Kumet R; Gelenberg AJ
    Essent Psychopharmacol; 2005; 6(2):104-11. PubMed ID: 15765794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACOG Committee Opinion No. 375: Brand versus generic oral contraceptives.
    Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists
    Obstet Gynecol; 2007 Aug; 110(2 Pt 1):447-8. PubMed ID: 17666623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal of sibutramine. Editorial is judgment in advance of the facts.
    Finer N;
    BMJ; 2010 Mar; 340():c1346. PubMed ID: 20219799
    [No Abstract]   [Full Text] [Related]  

  • 11. Polymorphism in generic drug product development.
    Snider DA; Addicks W; Owens W
    Adv Drug Deliv Rev; 2004 Feb; 56(3):391-5. PubMed ID: 14962588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Withdrawal of sibutramine. Magic bullets now uncontrolled.
    Garrow JS
    BMJ; 2010 Mar; 340():c1351. PubMed ID: 20219800
    [No Abstract]   [Full Text] [Related]  

  • 13. [Bioequivalence studies of pharmaceutical preparations].
    Vetchý D; Frýbortová K; Rabisková M; Danecková H
    Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.
    Duh MS; Cahill KE; Paradis PE; Cremieux PY; Greenberg PE
    Expert Opin Pharmacother; 2009 Oct; 10(14):2317-28. PubMed ID: 19663636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
    Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane.
    Taylor PW; Keenan MH
    Curr Med Res Opin; 2006 Mar; 22(3):603-15. PubMed ID: 16574043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
    Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations concerning the introduction of generic formulations of cyclosporine.
    Kahan BD
    Transplant Proc; 1999 May; 31(3):1634; discussion 1675-84. PubMed ID: 10331030
    [No Abstract]   [Full Text] [Related]  

  • 19. What's the problem with generic antiepileptic drugs?: a call to action.
    Berg MJ
    Neurology; 2007 Apr; 68(16):1245-6. PubMed ID: 17438211
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety pharmacology of sibutramine mesylate, an anti-obesity drug.
    Kim EJ; Park EK; Suh KH
    Hum Exp Toxicol; 2005 Mar; 24(3):109-19. PubMed ID: 15901050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.